Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amphastar Pharmaceuticals Inc (AMPH) vs Commvault Systems Inc (CVLT) Price & Performance

Amphastar Pharmaceuticals IncTrade
Commvault Systems IncTrade

Price performance (Past 24H)

Key statistics

Amphastar Pharmaceuticals Inc vs Commvault Systems Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Commvault Systems Inc trades at $139.62 (market cap $5.78B). The key difference: Commvault Systems Inc is far larger — about 6.7× Amphastar Pharmaceuticals Inc's market cap, and Commvault Systems Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

AMPHCVLT
Market Cap
$863.95M$5.78B
Sector
HealthTechnology
52-Week High
$30.81$195.41
52-Week Low
$16.87$75.18
Enterprise Value
$1.26B$5.77B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amphastar Pharmaceuticals Inc

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

Commvault Systems Inc

Commvault Systems (CVLT) trades at $135.27, up 1.43% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with an 81.09% gross margin and 32.77% ROE, though valuation multiples like a P/E of 89.38 are elevated. Recent news highlights growth in SaaS revenue and new security integrations, such as the Threat Scan partnership with Google, driving positive analyst sentiment.

The outlook remains positive with a consensus price target of $172.40, implying 27% upside, supported by subscription growth and cash flow improvements. Risks include high valuation sensitivity, competitive pressures in data security, and fiduciary duty investigations noted in recent legal alerts, which could impact investor confidence near-term.

Returns comparison

Trailing returns across standard periods

About Amphastar Pharmaceuticals Inc

Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.

Read more on AMPH

About Commvault Systems Inc

Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.

Read more on CVLT